Trained as a immunologist, Anthony Williamson has over 25 years of experience as a discovery research scientist, entrepreneur and investor. As an academician, he held the position of Associate Professor at the Scripps Research Institute, where his laboratory studied antibody responses to infectious agents, including prion proteins. Anthony has co-founded and served as CEO of three biotechnology companies (Prion Solutions (acquired by Chiron), Calmune Corporation, and latterly AlphaBiomics).  In the pharma setting he was Head of Technology, Prevention, at Janssen Pharmaceuticals, Johnson and Johnson.  He serves as the Partner responsible for biopharma investments at Skyviews Life Science, a privately held advisory company specialized in precision health and longevity.

Dr. Williamson graduated with a Ph.D. in molecular immunology from the University of Sheffield, UK, and completed his post-doctoral training at Scripps Research Institute, La Jolla, where he was a Donald E. and Delia B. Baxter Research Fellow.